Market news

Soon-Shiong owned 65.5% of ImmunityBio as of its April proxy record date.

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nant Capital’s investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong’s new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans. ImmunityBio’s share price has cooled slightly in the very short term, with a 1-day share price return of 2.75% and a 7-day share price return of 1.81%. However, the 30-day and 90-day share price returns of 7.53% and 16.45% suggest momentum is still building...

ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.

ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ImmunityBio looks attractive due to ANKTIVA's FDA approval for BCG-unresponsive NMIBC and pipeline expansion potential. See why I rate IBRX stock a Buy.

Patrick Soon-Shiong said the trial has been fully accrued and passed its one-year mark.

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.

ImmunityBio’s record quarterly revenue of $51.2 million beat Wall Street’s estimates of $49.7 million, driven by the increased sales of Anktiva.

ImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio: Q2 Earnings Snapshot

ImmunityBio secures UAE marketing authorization for ANKTIVA across two cancer indications, expanding treatment options for NMIBC and NSCLC.

ImmunityBio (NASDAQ:IBRX) shares climbed 7. 5% on Thursday after the company announced that the United Arab Emirates had granted marketing approval for ANKTIVA in two cancer indications, further expanding the therapy’s international regulatory reach.

CULVER CITY, Calif., July 29, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA® (nogapendekin alfa inbakicept) across two indications. The authorization covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC, and ANKTIVA 1.2 mg in combination with i

ImmunityBio’s stock has surged 282.7% year to date, yet its overall valuation checks sit at a mixed 3 out of 6. This leaves investors weighing a powerful momentum story against signals that do not clearly flag the shares as cheap or expensive. The year to date gain of 282.7% suggests expectations around ImmunityBio have reset sharply higher. Fresh buyers are now paying a far richer price than they would have earlier in the year. Speculation around Anktiva’s potential role in bladder cancer...

Sheets Smith Wealth Management cut its IBRX stake by 7.2% to 512,572 shares.